StockData
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc. (KYTX) stock

KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30
$4.26−0.11 (-2.52%)

Close on Nov 20, 2026Market cap $263.45MP/E –Yield –

Kyverna Therapeutics net income

Net income is the profit left for shareholders after every expense, interest and tax.

Kyverna Therapeutics's net income for the twelve months ending Sep 30, 2026 was -$157.79M. For fiscal 2025 it was -$161.31M.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$161.31M–
FY2024Dec 31, 2024-$127.48M–
FY2023Dec 31, 2023-$60.37M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$41.94M–
Q2 FY2026Jun 30, 2026-$38.32M–
Q1 FY2026Mar 31, 2026-$39.73M–
Q4 FY2025Dec 31, 2025-$37.80M–
Q3 FY2025Sep 30, 2025-$36.79M–
Q2 FY2025Jun 30, 2025-$42.08M–
Q1 FY2025Mar 31, 2025-$44.64M–
Q4 FY2024Dec 31, 2024-$37.49M–
Q3 FY2024Sep 30, 2024-$34.49M–
Q2 FY2024Jun 30, 2024-$28.80M–
Q1 FY2024Mar 31, 2024-$26.69M–
Q4 FY2023Dec 31, 2023-$20.67M–
Q3 FY2023Sep 30, 2023-$15.47M–
Q2 FY2023Jun 30, 2023-$13.09M–
Q1 FY2023Mar 31, 2023-$11.14M–

More Kyverna Therapeutics figures

See a number that looks wrong?